SOURCE: Aradigm Corporation

May 15, 2007 16:05 ET

Aradigm to Present at Wall Street Analyst Forum on May 22

Webcast Scheduled May 22 at 2:00 P.M. Eastern Time

HAYWARD, CA -- (MARKET WIRE) -- May 15, 2007 -- Aradigm Corporation (OTCBB: ARDM) today announced that the Company's President and Chief Executive Officer, Igor Gonda, Ph.D. will present at the Wall Street Analyst Forum on Tuesday May 22, 2007 at 2:00 p.m. Eastern Time (11:00 a.m. Pacific time). The conference is being held at the Princeton Club in New York City.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, asthma, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. Novo Nordisk also remains a substantial shareholder and investor in Aradigm. More information about Aradigm can be found at www.aradigm.com.

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and AERx are registered trademarks of Aradigm.